Tumor-targeting therapy can be an efficacious way to cure a malignant tumor in clinical trials. Phage display is a molecular diversity technology that allows the presentation of a large number of peptides or proteins on the surface of filamentous phage for various applications. In this study, we report on using phage display to generate peptide libraries that bind to colon cancer tissues. To accomplish this, we developed a screening protocol that contained 3 rounds of in vitro positive panning on colon cancer cells (SW480) and 2 rounds of subtractive screening in vitro on normal human intestinal epithelial cells with a phage display-7 peptide library. After several rounds of panning, both phage titer and recovery efficiency were significantly improved. Through a cell-based enzyme-linked immunosorbent assay, immunofluorescence, in vivo binding assay, immunocytochemical staining, and immunohistochemical staining, peptide CP15 (VHLGYAT) was demonstrated to be the most effective peptide in targeting tumor cells (SW480 and HT29 cells) and tumor tissues but not the normal human intestinal epithelial cells and control colon tissue. These studies suggest that peptide CP15 may be a promising lead candidate in the development of a useful colon tumor diagnostic and targeted drug delivery agent. (Journal of Biomolecular Screening 2007:429-435) 
INTRODUCTION
C OLON CANCER is the 2nd-leading cause of cancer-related deaths in Europe and the United States. It ranks 2nd in incidence to lung cancer in men and breast cancer in women. 1 The main goal of cancer therapy currently is to eradicate cancer cells while sparing normal tissues. This process requires the selective targeting of cancer cells at the site of malignancy. 2 Certain membrane ligands are expressed specifically in cancer cells, which are useful as anticancer targets. The major drawback of current cytotoxic and gene therapy vectors is their immunogenicity and lack of selectivity. 3, 4 Development of methods for identifying ligands specific for tumor biomarkers that can discriminate between normal and cancerous cells is an effective way to overcome the major drawback of current cytotoxicity and gene therapy. Early work to develop targeting molecules has focused on the use of antibodies for tumor recognition and drug delivery. 5, 6 Because of the immunogenicity and specific binding ability of antibodies in patients, this is not an ideal treatment.
The use of small peptides may circumvent these shortcomings because they are typically nonimmunogenic and combine high affinity and selectivity with more desirable pharmacokinetic properties. Furthermore, specific targeting of tumor cells using highaffinity and highly selective peptides conjugated to conventional chemotherapeutics enables the use of low doses, eliminating the toxic effects of chemotherapeutics such as doxorubicin. 7 Phage display is a molecular diversity technology that allows the presentation of a large number of peptides or proteins on the surface of filamentous phage for various applications. These libraries permit the selection of peptides or proteins with high affinity and specificity for almost any target. The most important feature of this technology is the direct link between the experimental phenotype and its encapsulated genotype. 8 The display of peptide libraries on the surface of bacteriophage offers a way of searching for peptides with specific binding properties. In the past few years, panning phage-displayed peptide libraries on intact cells in culture and on the tissues of living animals has proven to be successful for isolating peptides that show high cell specificity and tissue specificity. [9] [10] [11] In this study, we have used in vitro panning to identify peptides that distinguish between human intestinal epithelial cells 12 and colon carcinoma cells (SW480). 13 Using a method of selection and subtraction, we have isolated peptides that can target the 2 colon cancer cell lines (SW480, HT29), pointing to its great potential in novel diagnostics and therapeutics of colon cancer.
MATERIALS AND METHODS

Materials
The colon cancer cell lines HT29 and SW480 were obtained from the cell bank of Xiangya School of Medicine, Central South University (Changsha, China). HT29 and SW480 cell lines were maintained in medium supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine at 37 °C in 5% CO 2 .
The ex vivo culture of primary human intestinal epithelial cells was based on the method described by Grossmann and others. 12 Six-to 8-week-old BALB/C mice were obtained from the Department of Laboratory Animal Science of Xiangya School of Medicine. Mice were maintained at room temperature under 40% humidity. The Medical Laboratory Animal Management Committee of Xiangya School of Medicine, Central South University, approved all animal procedures.
The Ph.D.-7™ phage display peptide library was purchased from New England BioLabs (Beijing, China). Fetal calf serums (FCS) and RPMI-1640 medium were from HyClone (Changsha, China). Peptides CP15 (VHLGYAT) and A1 (HSFPFPL, a nonspecific peptide control) were synthesized and labeled with fluorescein isothiocyanate (FITC) by Sangon Biosciences Ltd. (Shanghai, China). The generic laboratory products and reagents such as FBS, L-glutamine, bovine serum albumin (BSA), Tris-HCl, and so forth were from Clonetimes Biotech Co. Ltd. (Changsha, China).
Phage DNA isolation and sequencing were performed by Sangon Bioengineering Ltd. (Shanghai, China). FITC-conjugated sheep antimouse antibody and horseradish peroxidase (HRP)conjugated sheep antimouse Ig were purchased from Sangon Bioengineering Ltd. (Shanghai, China). Mouse anti-M13 bacteriophage antibody was purchased from New England BioLabs.
Escherichia coli host strain ER2738 (a robust F + strain with a rapid growth rate; New England Biolabs, Beijing, China) was used for M13 phage propagation.
In vitro panning
SW480 cells and control normal human intestinal epithelial cells were cultured in RPMI 1640 10% FCS at 37 °C in a humidified atmosphere containing 5% CO 2 . The cells were washed with tris-buffered saline Tween-20 (TBST; 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Tween-20) and kept in serum-free RPMI 1640 for 1 h before use.
Then, the solution (7-mer Ph.D. phage-displayed peptide library) that contains 10 11 pfu and 5% BSA was added into cells at 37 °C for 1 h. Next, unbound phages were wiped off by washing with TBST for about 5 times. The bound phages were collected together with target cells by digestion with 0.25% trypsin.
Two microliters of collected phages was picked out for phage tittering. The titer of phage was evaluated by blue plaque-forming assay on an agar plate containing tetracycline. For the amplification of selected phage clones to be used in the next round of panning, the remaining cells and phages were mixed with 20 ml of E. coli ER2738 culture and incubated at 37 °C with vigorous shaking for 4.5 h. After the 1st round of panning, the phages were treated with normal human intestinal epithelial cells in the same way for subtractive screening, and the unbound phages were collected to eliminate the phages that can bind to liver cells. The residual phages were amplified and titered for the next round of panning. After 3 rounds of panning and 2 rounds of subtractive screening, the peptide sequences of randomly picked phage clones were analyzed by cell-enzyme-linked immunosorbent assay (ELISA).
Cell-ELISA
SW480 cells and control human intestinal epithelial cells were cultured in RPMI 1640 at 37 °C and plated into a 96-well plate (1 × 10 4 cells/well) the day before use. Cells were washed, incubated in serum-free RPMI 1640 at 37 °C for 1 h, and fixed in 4% of paraformaldehyde in PBS for 15 min. Cells were washed 3 times with TBST and blocked with blocking buffer (TBST contained 3% BSA) at 37 °C for 1 h. The amplified phage clones picked out randomly were each added into the cells at 10 10 pfu/well, and the plate was incubated at 37 °C for 1.5 h. Subsequently, unbound phage was removed by washing the plate 3 times with TBST. To detect phage bound to the cells, wells were incubated for 1 h with 100 µl/well of mouse anti-M13 antibody (diluted 1:5000 in the blocking buffer). After washing the plate 3 times with TBST, 100 µl HRP-conjugated sheep antimouse Ig was added to each well (diluted 1:500 in the blocking buffer). Subsequently, color development was carried out by adding 100 µl/well of freshly prepared diaminobenzidine (DAB) solution and incubating the plate for 5 min at 37 °C. The plates were read on an automated ELISA plate reader at the absorbency of 490 nm. Phosphate-buffered saline (PBS) and unrelated phages with the same titer were added into wells instead of the selected phage clones as negative controls. Triplicate determinations were done at each data point. Selectivity is determined using the formula: selectivity = OD A1 -OD C1 /OD A2 -OD C2 .
Here, OD A1 and OD C1 represent the OD values from the binding to SW480 cells by the selected phage and control phage, respectively; OD A2 and OD C2 represent the OD values from the binding to control cell line intestinal epithelial cells by the selected phage and control phage, respectively.
Immunocytochemical staining
SW480, HT29, and intestinal epithelial cells were all digested with 0.25% trypsin and plated on coverslips overnight. Cells were washed 3 times with PBS and fixed with acetone at 4 °C for 20 min before immunocytochemistry. Then, about 1 × 10 11 pfu of phage CP15 diluted in PBS was added onto the slips and incubated at 4 °C overnight before slips were washed by TBST 5 times. The following protocol was similar to immunohistochemical staining described below.
Cell immunofluorescence
Immunofluorescence microscopy was used to study the affinity of synthetic peptides binding to HT29 and SW480 cells. SW480, HT29, and intestinal epithelial cells were all digested with 0.25% trypsin and plated on coverslips overnight. Cells were washed 3 times with PBS and fixed with acetone at 4 °C for 20 min before analysis. The synthetic peptides labeled with FITC were incubated with cells, following the same protocol used for antibodies, as described above. PBS and control peptides labeled with FITC were used as negative controls. After washing 3 times with PBS, the slips were observed in the fluorescence microscope (Leica, Solms, Germany).
In vivo binding assay
SW480 colon cancer cells were inoculated subcutaneously on the back of BALB/C mice. When tumors reached the size of 1 cm in diameter, a selected targeting phage clone (10 11 pfu) was injected into the tail veins of tumor-bearing mice. After 15 min, mice were killed (5 mice were used for negative control) and perfused through the heart with 100 ml of D-Hank's buffer.
For immunohistochemistry analysis, tumors were recovered, sectioned in a cryostat at -20 °C, mounted on poly-L-lysine-coated glass microslides, and fixed in ice-cold acetone for 10 min for hematoxylin-eosin staining and immunohistochemistry.
The slips were blocked by H 2 O 2 (3% in PBS) at room temperature for 5 to 10 min. After being washed by PBS for 5 min at 37 °C, the slips were incubated with normal sheep serum for 20 min at 37 °C. Subsequently, the slips were incubated overnight at 4 °C with mouse anti-M13 phage antibody with a work dilution of 1:1000. On the following day, the slips were rinsed 3 times (10 min for each rinse) in PBS and incubated with secondary antibody for 1 h at room temperature. Afterward, the slips were rinsed 3 times (5 min for each rinse) in PBS. The bound antibody was visualized using DAB (3,3-diaminobenzidine tetrachloride; Sigma Chemicals, St. Louis, MO) in PBS containing 0.03% H 2 O 2 . Finally, slips were rinsed for 10 min in running tap water before dehydration and mounting.
RESULTS
Specific enrichment of colon cancer cell-bound phages
Phage clones that can bind to colon cancer cells were isolated by 3 rounds of positive panning and 2 rounds of subtractive screening in vitro. In each round, the bound phages were rescued and amplified in ER2738 for the following round of panning, whereas the unbound phages were cleared via washing with TBST. Both phage titer and recovery efficiency were significantly improved after each round of panning (Fig. 1) . The number of phages recovered from colon cancer cells increased 584-fold (from 0.9 × 10 4 pfu to 5.26 × 10 6 pfu) compared with that of recovered phages in the 1st round, as shown in Figure 1 . The output-input ratio of phages after each round of panning was used to determine the phage recovery efficiency, which increased from 2.3 × 10 -8 to 3.3 × 10 -5 ( Table 1) . Approximately 50 phage clones were randomly picked for sequencing and more analysis, and each of the clones and corresponding exogenous sequence was named as CP01 to CP50.
Confirmation of in vitro binding by cell-based ELISA
To confirm the binding ability of selected phage clones to HT-29, 50 independent phage clones that were randomly picked after the 3rd in vitro panning were tested by cell-ELISA. Human intestinal epithelial cells were used as a control for calculating selectivity. Clones CP08, CP15, CP22, CP31, CP40, and CP47 appeared to bind better than the other clones (Fig. 2) . When the sequences of these clones were identified by DNA sequencing, it was found that CP08 (same as CP47), CP15, CP22, CP31, and CP40 contained the peptide sequences KTYQGPL, VHLGYAT, The output ratio was calculated as output number/input number. PHLNYSR, ANHTSPV, and PHPLYQS, respectively. Multiple sequence alignment analysis did not reveal any strong homology among all the peptides ( Table 2) . Only some short motif such as YQ/HL/SP could be found. The phage CP15 and its displaying peptide VHLGYAT were further analyzed.
Phage binding assay by cell immunocytochemical staining
To confirm the binding ability of the selected phage to target colon cancer cells (HT29 and SW480 cells), phage clone CP15 was picked out for immunochemical assay. Intestinal epithelial cells were used as the negative control. The interaction of CP15 and colon cancer cells was evaluated by immunocytochemical staining. As shown in Figure 3 , the phage CP15 binding to colon cancer cells (HT29 and SW480 cells) was positively staining dark brown, which was located at the surfaces and in the perinuclear cytoplasm of cells. In contrast, no positive staining or light brown positive staining was observed on the control intestinal epithelial cells.
Specific binding ability of peptides to colon cancer cells
Similar to the results of the experiment above, we found that phage CP15 specifically bound to colon cancer cells. So it is important to examine whether the same free peptide can maintain the binding specificity when it is removed from the phage protein framework. To do so, 2 synthetic CP15 (VHLGYAT) and A1 (HSFPFPL, a nonspecific phage control) peptides were made with a fluorescent (FITC) label attached to each peptide's end. Cells were examined using fluorescence microscopy after being incubated with HT29, SW480, and intestinal epithelial cells (Fig. 4) . Specific fluorescence staining was seen on the membrane and in the perinuclear cytoplasm of the HT29 and SW480 cells, but there was no significant green fluorescence on the control cells and FITC-labeled peptide A1 with all cell lines above. These results suggested that the free peptide CP15 could bind specifically to several kinds of colon cancer cell lines.
In vivo binding assay
CP15 was chosen for further in vivo binding studies. The specificity of the phage clone was further confirmed by immunohistochemical staining of bound phage in the tumor tissue in comparison to colon tissue. From the data shown in Figure 5 , the tumor tissue sections were stained brown distinctly, whereas the normal colon tissue sections stained with CP15 phage clone showed negative staining.
DISCUSSION
The selective delivery of toxic agents to cancer cells provides an ideal approach to enhance therapeutic efficacy and minimize adverse side effects. Because cancer cells can display certain cell surface antigens in higher numbers, these structures represent potential sites for delivery of toxic agents. To establish efficient and reliable therapeutic drug delivery into cancer cells, a number of delivery agents has been investigated in recent years. 14 Among them, phage display approaches, which were introduced by Smith, 15 have shown great potential for isolating antibodies or peptides that recognize specific target molecules.
In this study, we successfully developed a screening protocol that uses selection and subtraction on intact, viable cells, resulting in a peptide CP15 (VHLGYAT) that binds to colon cancer. The screening protocol used 3 rounds of in vitro panning on colon cancer cells and 2 rounds of subtractive screening in vitro on normal human intestinal epithelial cells. The optimizing procedures (several rounds of whole-cell subtractive screening and enhanced selection pressures, etc.) were performed to improve the probability of obtaining specific phages with high affinity. This is different from other previously reported phage display library panning strategies. 16 After 3 rounds of panning, approximately 50 clones were chosen for further characterization. First, we used cell-ELISA to confirm the specific binding of SW480 cells in vitro. The best candidate, clone CP15, was then selected for immunocytochemical and in vivo phage binding assay. Next, immunocytochemical and immunohistochemical staining were used to confirm the selectivity of the phage CP15 to HT29 and SW480 cells and tumor tissue compared to intestinal epithelial cells and control colon tissue. Furthermore, we demonstrated that the synthetic peptide FITC-CP15 was able to maintain the binding specificity to HT29 and SW480 cells in vitro, proving that the binding ability was determined by the peptide sequence alone without the involvement of flanking phage coat protein sequences. Under the same condition, the normal intestinal epithelial cell tested did not show any significant fluorescence, which further confirmed the targeting of peptide FITC-CP15 to colon cancer cells. The coupling of peptides, such as CP15, to an antitumor drug may produce a colon cancer-selective agent with a greater therapeutic effect. Arap and others 7, 17 have shown that conjugating drugs to peptides selective for angiogenic markers eliminated tumors in vivo by destroying their vasculature. However, tumors smaller than 1 mm 3 can persist without a vasculature by receiving nutrients from adjacent normal blood vessels, thus escaping targeting of the vasculature. 17 Thus, peptides capable of tumor cell-selective delivery of antitumor drug may provide an important complement to antiangiogenic strategies. Compared with in vivo phage display technology, cell-based panning is simple and effective. The capillary vessel of the vascular system could be a big barrier for the phage to pass through, so most of the recovered phages selective for angiogenic markers are actually binding to the vascular endothelium cells but not tumor cells. Many-specifically vascular endothelium cell-binding peptides have been reported by using in vivo phage display technology. 18 We chose intact tumor cells as targets to panning peptides specific to colon cancer tissues in this study. As demonstrated by the results of specific binding assays, the targeting peptide CP15 may have the potential for the diagnosis and anticancer therapy of colon tumors and for other further research in this field.
